NCT00951054已完成2 期
A Phase II Study of NK012 in Locally Advanced Non-Resectable and Metastatic Breast Cancer Patients With Triple Negative Phenotype
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 61
- 试验地点
- 2
- 主要终点
- Antitumor activity (overall response rate) of NK012
研究概览
简要总结
The purpose of this study is to determine whether NK012 is safe and effective in the treatment of advanced and metastatic triple negative breast cancer.
详细描述
This is a Phase II, open label, single arm, multicenter study of NK012 in patients with locally advanced non-resectable and metastatic breast cancer with ER-negative, PR negative and HER2-negative phenotype. NK012 will be administered by infusion over 30 minutes once every 28 days (on Day 1 of each cycle). Patients will be screened for UGT1A1 polymorphism prior to enrollment in order to determine their starting dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed diagnosis of breast cancer with locally advanced disease for which there is no surgical option, or stage IV disease.
- •ER-negative and PR-negative (defined as less than or equal to 10% tumor staining).
- •HER2-negative defined as one of the following:
- •0 or 1+ IHC;
- •2+ or 3+ IHC and FISH negative (ratio < 2.2);
- •or FISH negative (ratio < 2.2).
- •No less than one and no more than two prior chemotherapy regimens for advanced or metastatic disease.
- •Prior chemotherapy must have included a taxane either as part of an adjuvant regimen or as part of a metastatic disease regimen.
- •Interval from last dose of prior treatment to enrollment in this study must be at least 4 weeks for cytotoxic chemotherapy (exception: 6 weeks for nitrosoureas or mitomycin C), 5 half-lives for non-cytotoxic therapy (to be reviewed by the Medical Monitor to establish start date), and 4 weeks for monoclonal antibodies; patients must have recovered from all acute toxicities.
- •Measurable disease by RECIST.
- •ECOG performance status of 0-
- •Females at least 18 years of age.
- •Adequate bone marrow function as defined by absolute neutrophil count of greater than or equal to 1,500/ mm^3 and platelets of greater than or equal to 100,000/mm^
- •AST(SGOT) and ALT(SGPT) levels no greater than 3 x the institutional ULN, and total bilirubin less than or equal to 1.5 x ULN.
- •Serum creatinine less than or equal to 1.5 x ULN, or creatinine clearance greater than or equal to 60 mL/min (Cockcroft-Gault formula) for patients with serum creatinine levels > 1.5 x ULN.
- •Able to understand and show willingness to sign a written informed consent document.
- •Exclusion criteria:
- •Patient has Gilbert's Syndrome.
- •Concurrent use of other investigational agent.
- •History of brain metastases or spinal cord compression, unless irradiated a minimum of 4 weeks before study entry and stable without requirement for corticosteroids for > 1 week.
- •Prior exposure to topoisomerase 1 inhibitors (i.e., irinotecan, topotecan, camptothecin).
- •Concurrent serious infections requiring parenteral therapy.
- •Pregnant or of childbearing potential and not using methods to avoid pregnancy. A negative pregnancy test (urine or serum) must be documented at baseline for women of childbearing potential. Patients may not breast-feed infants while on this study.
- •Significant cardiac disease including heart failure that meets New York Heart Association (NYHA) class III and IV definitions, history of myocardial infarction within one year of study entry, uncontrolled dysrhythmias or poorly controlled angina.
- •History of serious ventricular arrhythmia (VT or VF, greater than or equal to 3 beats in a row), QTc greater than or equal to 450 msec for men and 470 msec for women, or LVEF less than or equal to 40% by MUGA or ECHO.
排除标准
- 未提供
结局指标
主要结局
Antitumor activity (overall response rate) of NK012
时间窗: At baseline and after every 2 cycles; PR or CR must be confirmed no less than 4 weeks after the first response was recorded
次要结局
- Duration of response(Monthly for 6 months after patient goes off study, then every 3 months thereafter)
- Rate and duration of disease control(Monthly for 6 months after patient goes off study, then every 3 months thereafter)
- Time to disease progression(Monthly for 6 months after patient goes off study, then every 3 months thereafter)
- Toxicity profile of NK012(Duration of study, and up to 30 days after discontinuation)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Study of NK012 in Patients With Refractory Solid TumorsCancerNCT00542958Nippon Kayaku Co., Ltd.39
已完成
2 期
A Study of NK012 in Patients With Relapsed Small Cell Lung CancerSmall Cell Lung CancerNCT00951613Nippon Kayaku Co., Ltd.72
进行中（未招募）
2 期
OM202JP Clinical Study of KNP2002Common WartNCT05896215KinoPharma Inc.159
已完成
2 期
A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or CarcinosarcomaEndometrial CancerUterine CancerCarcinosarcomaOvarian CancerNCT03395080Leap Therapeutics, Inc.111
终止
1 期
NXP800 for the Treatment of Patients With Advanced or Metastatic CholangiocarcinomaNCT06420349Mayo Clinic7